EsoCap announces publication of comprehensive Phase II results demonstrating ESO-101’s effectiveness in eosinophilic esophagitis
December 17, 2024 05:00 ET
|
EsoCap AG
Detailed results of the ACESO Phase II study published in the peer-reviewed medical journal Alimentary Pharmacology & TherapeuticsESO-101 leverages EsoCap’s unique drug delivery technology to...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
September 20, 2024 07:45 ET
|
Regeneron Pharmaceuticals, Inc.
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements seen in...
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
June 26, 2024 17:30 ET
|
Regeneron Pharmaceuticals, Inc.
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only...
Eosinophilic Esophagitis Market Size to Surpass US$ 941.8 million by 2031 - Growth Plus Reports
February 09, 2024 05:30 ET
|
Growth Plus Reports
Pune, Feb. 09, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Eosinophilic Esophagitis Market is expected to clock US$ 941.8 million by 2031 and...
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
January 25, 2024 14:29 ET
|
Regeneron Pharmaceuticals, Inc.
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...
EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis
December 05, 2023 03:00 ET
|
EsoCap AG
ESO-101, EsoCap's lead product candidate, consists of a capsule with a rolled-up, thin mucoadhesive film with the anti-inflammatory corticosteroid, mometasone furoateEsoCap's novel targeted delivery...
Eosinophilic Esophagitis Market to Show Positive Growth by 2032, Examines DelveInsight | Key Companies - Bristol Myers Squibb, Ellodi, AstraZeneca, Kyowa Kirin, Allakos, Pfizer, Revolo, EsoCap AG, NexEos Diagnostics, Celgene
September 28, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Eosinophilic Esophagitis Market to Show Positive Growth by 2032, Examines DelveInsight | Key Companies - Bristol Myers Squibb, Ellodi, AstraZeneca,...
EsoCap completes patient recruitment in ACESO Phase II trial in eosinophilic esophagitis
September 05, 2023 03:30 ET
|
EsoCap AG
EsoCap's novel targeted delivery platform is designed to increase mucosal contact time and drug deposition in the esophagus ESO-101, EsoCap's lead product candidate, consists of a capsule with a...
An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
August 15, 2023 15:40 ET
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
New Study on the Current State of Health Care for Eosinophilic Esophagitis
May 18, 2023 15:03 ET
|
Asthma and Allergy Foundation of America
Washington, D.C., May 18, 2023 (GLOBE NEWSWIRE) -- A groundbreaking report reveals challenges and barriers to timely diagnosis and effective treatment and management of a rare, but increasing...